SEARCH

SEARCH BY CITATION

References

  • 1
    Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide, Version 2.0. Lyon: IARC Press, 2004. IARC Cancer Base No. 5.
  • 2
    Correa P. Human gastric carcinogenesis: a multistep and multifactorial process—First American Cancer Society Award Lecture on cancer epidemiology and prevention. Cancer Res 1992; 52: 673540.
  • 3
    IARC monographs on the evaluation of the carcinogenic risks to humans. Schistosomes, liver flukes and Helicobacter pylori. Volume 61. Lyon: International Agency for Research on Cancer, 1994: 177241.
  • 4
    González CA, Sala N, Capellá G. Genetic susceptibility and gastric cancer risk. Int J Cancer 2002; 100: 24960.
  • 5
    Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984; 1: 131115.
  • 6
    Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, Sibley RK. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991; 325: 112731.
  • 7
    Sipponen P. Gastric cancer—a long-term consequence of Helicobacter pylori infection? Scand J Gastroenterol 1994; 201 ( Suppl): 247.
  • 8
    Kuipers EJ, Uyterlinde AM, Pena AS, Roosendaal R, Pals G, Nelis GF, Festen HP, Meuwissen SG. Long-term sequelae of Helicobacter pylori gastritis. Lancet 1995; 345: 15258.
  • 9
    Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case-control studies nested within prospective cohorts. Gut 2001; 49: 34753.
  • 10
    Eslick GD, Lim LL, Byles JE, Xia HH, Talley NJ. Association of Helicobacter pylori infection with gastric carcinoma: a meta-analysis. Am J Gastroenterol 1999; 94: 237379.
    Direct Link:
  • 11
    Huang JQ, Sridhar S, Chen Y, Hunt RH. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 1998; 114: 116979.
  • 12
    Webb PM, Crabtree JE, Forman D, the EUROGAST Study Group. Gastric cancer, cytotoxin-associated gene A-positive Helicobacter pylori, and serum pepsinogens: an international study. Gastroenterology 1999; 116: 26976.
  • 13
    Correa P, Schneider BG. Etiology of gastric cancer: what is new? Cancer Epidemiol Biomarkers Prev 2005; 14: 186568.
  • 14
    Blaser MJ, Perez-Perez GI, Kleanthous H, Cover TL, Peek RM, Chyou PH, Stemmermann GN, Nomura A. Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Res 1995; 55: 211115.
  • 15
    Parsonnet J, Friedmann GD, Orentreich N, Vogelman H. Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection. Gut 1997; 40: 279301.
  • 16
    Enroth H, Kraaz W, Engstrand L, Nyren O, Rohan T. Helicobacter pylori strain types and risk of gastric cancer: a case-control study. Cancer Epidemiol Biomarkers Prev 2000; 9: 9814.
  • 17
    Ogura K, Maeda S, Nakao M, Watanabe T, Tada M, Kyutoku T, Yoshida H, Shiratori Y, Omata M. Virulence factors of Helicobacter pylori responsible for gastric diseases in Mongolian gerbil. J Exp Med 2000; 192: 160110.
  • 18
    Huang JQ, Zheng GF, Sumanac K, Irvine EJ, Hunt RH. Meta-analysis of the relationship between cagA seropositivity and gastric cancer. Gastroenterology 2003; 125: 163644.
  • 19
    Amieva MR, Vogelmann R, Covacci A, Tompkins LS, Nelson WJ, Falkow S. Disruption of the epithelial apical-junctional complex by Helicobacter pylori CagA. Science 2003; 300: 143034.
  • 20
    Stein M, Bagnoli F, Halenbeck R, Rappuoli R, Fantl WJ, Covacci A. c-Src/Lyn kinases activate Helicobacter pylori CagA through tyrosine phosphorylation of the EPIYA motifs. Mol Microbiol 2002; 43: 97180.
  • 21
    Higashi H, Tsutsumi R, Muto S, Sugiyama T, Azuma T, Asaka M, Hatakeyama M. SHP-2 tyrosine phosphatase as an intracellular target of Helicobacter pylori CagA protein. Science 2002; 295: 6836.
  • 22
    Masanori H. Helicobacter pylori CagA—a bacterial intruder conspiring gastric carcinogenesis. Int J Cancer 2006; 119: 121723.
  • 23
    Bagnoli F, Buti L, Tompkins L, Covacci A, Amieva MR. Helicobacter pylori CagA induces a transition from polarized to invasive phenotypes in MDCK cells. Proc Natl Acad Sci USA 2005; 102: 1633944.
  • 24
    Broutet N, Plebani M, Sakarovitch C, Sipponen P, Megraud F, Eurohepygast Study Group. Pepsinogen A, pepsinogen C, and gastrin as markers of atrophic chronic gastritis in European dyspeptics. Br J Cancer 2003; 88: 123947.
  • 25
    Knight T, Wyatt J, Wilson A, Greaves S, Newell D, Hengles K, Corlett M, Webb P, Forman D, Elder J. Helicobacter pylori gastritis and serum pepsinogen levels in a healthy population; development of a biomarker strategy for gastric atrophy in high-risk groups. Br J Cancer 1996; 73: 81924.
  • 26
    Palli D, Decarli A, Cipriani F, Forman D, Amadori D, Avellini C, Giacosa A, Manca P, Russo A, Salkeld RM. Plasma pepsinogens, nutrients, and diet in areas of Italy at varying gastric cancer risk. Cancer Epidemiol Biomarkers Prev 1991; 1: 4550.
  • 27
    Aromaa A, Kosunen TU, Knekt P, Maatela J, Teppo L, Heinonen OP, Harkonen M, Hakama MK. Circulating anti-Helicobacter pylori immunoglobulin A antibodies and low serum pepsinogen I level are associated with increased risk of gastric cancer. Am J Epidemiol 1996; 144: 1429.
  • 28
    Varis K, Sipponen P, Laxen F, Samloff IM, Huttunen JK, Taylor PR, Heinonen OP, Albanes D, Sande N, Virtamo J, Harkonen M, Helsinki Gastritis Study Group. Implications of serum pepsinogen I in early endoscopic diagnosis of gastric cancer and dysplasia. Scand J Gastroenterol 2000; 35: 9506.
  • 29
    Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, Fahey M, Charrondiere UR, Hemon B, Casagrande C, Vignat J, Overvad K, Tjonneland A et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr 2002; 5: 111324.
  • 30
    Ferrari P, Kaaks R, Fahey MT, Slimani N, Day NE, Pera G, Boshuizen HC, Roddam A, Boeing H, Nagel G, Thiebaut A, Orfanos P et al. European Prospective Investigation into Cancer and Nutrition Study. Within- and between-cohort variation in measured macronutrient intakes, taking account of measurement errors, in the European Prospective Investigation into Cancer and Nutrition Study. Am J Epidemiol 2004; 160: 81422.
  • 31
    Slimani N, Kaaks R, Ferrari P, Casagrande C, Clavel-Chapelon F, Lotze G, Kroke A, Trichopoulos D, Trichopoulou A, Lauria C, Bellegotti M, Ocke MC et al. European Prospective Investigation into Cancer and Nutrition (EPIC) calibration study: rationale, design and population characteristics. Public Health Nutr 2002; 5: 112545.
  • 32
    Ghiara P, Rossi M, Marchetti M, Di Tommaso A, Vindigni C, Ciampolini F, Covacci A, Telford JL, De Magistris MT, Pizza M, Rappuoli R, Del Giudice G. Therapeutic intragastric vaccination against Helicobacter pylori in mice eradicates an otherwise chronic infection and confers protection against reinfection. Infect Immun 1997; 65: 49965002.
  • 33
    Gonzalez CA, Pera G, Agudo A, Bueno-de-Mesquita HB, Ceroti M, Boeing H, Schulz M, Del Giudice G, Plebani M, Carneiro F, Berrino F, Sacerdote C et al. Fruit and vegetable intake and the risk of stomach and oesophagus adenocarcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST). Int J Cancer 2006; 118: 255966.
  • 34
    González CA, Jakszyn P, Pera G, Agudo A, Palli D, Boeing H, Del Giudice G, Plebani M, Carneiro F, Nesi G, Berrino F, Vineis P et al. Meat and processed meat intake and the risk of stomach and oesophagus adenocarcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST). J Natl Cancer Inst 2006; 98: 34554.
  • 35
    Ye W, Nyren O. Risk of cancers of the oesophagus and stomach by histology or subsite in patients hospitalised for pernicious anaemia. Gut 2003; 52: 93841.
  • 36
    Ye W, Held M, Lagergren J, Engstrand L, Blot WJ, McLaughlin JK, Nyren O. Helicobacter pylori infection and gastric atrophy: risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia. J Natl Cancer Inst 2004; 96: 38896.
  • 37
    Nomura AMY, Kolonel LN, Miki LK, Stemmermann GN, Wilkens LR, Goodman MT, Perez-Perez GI, Blaser MJ. Helicobacter pylori, pepsinogen, and gastric adenocarcinoma in Hawaii. J Infect Dis 2005; 191: 207581.
  • 38
    Wu AH, Crabtree JE, Bernstein L, Hawtin P, Cockburn M, Tseng CC, Forman D. Role of Helicobacter pylori CagA+ strains and risk of adenocarcinoma of the stomach and esophagus. Int J Cancer 2003; 103: 81521.
  • 39
    Hansen S, Melby KK, Aase S, Jellum E, Vollset SE. Helicobacter pylori infection and risk of cardia cancer and non-cardia gastric cancer: a nested case-control study. Scand J Gastroenterol 1999; 34: 35360.
  • 40
    Limburg P, Qiao Y, Mark S, Wang G, Perez-Perez G, Blaser M, Wu Y, Zou X, Dong Z, Taylor P, Dawsey S. Helicobacter pylori seropositivity and subsite-specific gastric cancer risks in Linxian, China. J Natl Cancer Inst 2001; 93: 22633.
  • 41
    Knekt P, Teppo L, Aromaa A, Rissanen H, Kosunen TU. Helicobacter pylori IgA and IgG antibodies, serum pepsinogen I and the risk of gastric cancer: changes in the risk with extended follow-up period. Int J Cancer 2006; 119: 7025.
  • 42
    Malfertheiner P, Peitz U. The interplay between Helicobacter pylori, gastro-oesophageal reflux disease, and intestinal metaplasia. Gut 2005; 54 ( Suppl I): i13i20.